Space startup Varda raises $187 million in funding to make drugs in orbit

Space startup Varda raises 7 million in funding to make drugs in orbit


Pavlo Gonchar | Lightrocket | Getty Images

Space startup Varda announced on Thursday that it has raised $187 million in Series C funding, led by venture capital firms Natural Capital and Shrug Capital, to continue advancing drug manufacturing in space.

The latest round included participation from Peter Thiel, Lux Capital, Khosla Ventures and Caffeinated Capital. It brought the total capital Varda’s raised to $329 million.

“By expanding, we can support work on more complex molecules and ultimately increase cadence to achieve the turnaround times the pharmaceutical industry expects,” Chief Science Officer Adrian Radocea said in a press release Thursday.

Varda’s main mission is to launch and return drugs made in space. The startup has said the medicines crystallize differently in orbit due to the gravity differences, which would allow it to complete drugs that are currently difficult to manufacture.

In 2024, the space startup’s W-Series 1 capsule received FAA approval to return after successfully creating the drug Ritonavir the previous year.

So far, Varda said the company has been able to complete three space launches. Now, a fourth is in orbit, and the company expects to launch a fifth by the end of the year. Varda’s system uses Rocket Lab’s Photon spacecraft for its operation and adds its manufacturing module and a heatshield-protected capsule.

“With this capital, Varda will continue to increase our flight cadence and build out the pharmaceutical lab that will deliver the world’s first microgravity-enabled drug formulation,” said Varda CEO Will Bruey.

Varda Space Industries is the first company to process materials outside the International Space Station.

Recently, the space company has also operated a testbed for the U.S. government to use the W-series reentry vehicles to advance technology.

Varda said it has expanded into Huntsville, Alaska, and opened a laboratory in El Segundo, California, to begin work to crystallize more drugs.

“Our new lab space is an investment in our belief that in-space pharmaceutical manufacturing will drive the foundation of the orbital economy,” Radocea said.



Source

How Build-A-Bear went from a penny stock to a retail winner
Business

How Build-A-Bear went from a penny stock to a retail winner

Build-A-Bear Workshop wasn’t always a retail winner. The toy store, known for its interactive experience of building and accessorizing stuffed animals, has gone through a significant turnaround since CEO Sharon Price John took the helm of the company over a decade ago. “When I first came in 2013, that assessment of the brand was strong,” […]

Read More
Inside the dealmaking that pushed Trump to reclassify pot, expand access
Business

Inside the dealmaking that pushed Trump to reclassify pot, expand access

President Donald Trump’s move Thursday to sign an executive order easing federal restrictions on marijuana — and clearing the way for a Medicare pilot program covering CBD — caps a coordinated, yearlong push by the cannabis industry that combined traditional lobbying, sizable political donations, data-driven messaging and direct outreach to the president’s inner circle, industry […]

Read More
Shoppers are focusing on quality, not deals, in the final days before Christmas
Business

Shoppers are focusing on quality, not deals, in the final days before Christmas

While discounts drive purchasing in the early days of the holiday shopping season, consumers are shifting into more thoughtful, quality gifts in the back half of the season as total spending growth slows. U.S. consumers had spent $187.3 billion so far online between Nov. 1 and Dec. 12, up 6.1% from the same stretch last […]

Read More